Article
Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in pre-clinical individuals with a hypertrophic cardiomyopathy pathogenic variant: results of the ENERGY trial.
Cardiovascular research - 24 Oct 2025
van Driel Beau Olivier, Schoonvelde Stephan A C, Borodzicz-Jazdzyk Sonia, Huurman Roy, Visch Julia, Robbers Lourens, Harms Hans, Verhagen Judith, Vermeer Alexa, van den Aardweg Joost, van Rossum Albert C, Germans Tjeerd, Michels Michelle, van der Velden Jolanda
Abstract excerpt
AIMS: Previous studies have shown that individuals with a hypertrophic cardiomyopathy (HCM) pathogenic variant (PV) or likely pathogenic variant (LPV) without a HCM phenotype (PV/LPV carrier) have decreased myocardial external efficiency (MEE), which is thought to be a key pathomechanism in the onset and progression of HCM. Metabolic treatments improved exercise capacity in HCM patients, but evidence that such...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.